

1 **Implementation and extended evaluation of the Euroimmun Anti-**
2 **SARS-CoV-2 IgG assay and its contribution to the United Kingdom’s**
3 **COVID-19 public health response.**

4
5 Ashley David Otter^{1,2*}, Abbie Bown¹, Silvia D’Arcangelo^{1,2}, Daniel Bailey¹, Amanda
6 Semper³, Jacqueline Hewson², Matthew Catton¹, Prem Perumal¹, Angela Sweed¹,
7 Jessica Jones³, Heli Harvala⁴, Abigail Lamikanra⁴, Maria Zambon⁵, Nick Andrews⁵,
8 Heather Whitaker⁵, Ezra Linley⁶, Alexander J Mentzer^{7,8}, Donal Skelly^{8,9,10}, Julian C.
9 Knight⁷, Paul Klenerman⁹, **PHE Porton Euroimmun testing group**^{11†}, Gayatri
10 Amirthalingam⁵, Stephen Taylor¹², Cathy Rowe^{11,2}, Richard Vipond^{1,3}, Tim Brooks^{*3}.

11
12 * - corresponding authors: ashley.otter@phe.gov.uk, tim.brooks@phe.gov.uk

13 † - Complete list of authors listed in the appendix 1

14
15 1 – Diagnostic Support, National Infection Service, Public Health England, Porton, SP4 0JG
16 2 – SARS-CoV-2 serosurveillance laboratory, National Infection Service, Public Health England, Porton, SP4 0JG
17 3 – Rare and Imported Pathogens Laboratory, Public Health England, Porton, SP4 0JG
18 4 – NHS Blood and Transfusion, Microbiology Services, Colindale, UK
19 5 – Public Health England, Colindale, NW9 5EQ
20 6 – Seroepidemiology Unit, Public Health England, Manchester, M13 9WZ
21 7 – Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
22 8 – Oxford University Hospitals NHS Foundation Trust, Oxford, UK
23 9 – Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, UK
24 10 – Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
25 11 – National Infection Service, Public Health England, Porton, SP4 0JG
26 12 – Pathogen Immunology, Public Health England, Porton, SP4 0JG

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 1. Abstract

28 In March 2020, the Rare and Imported Pathogens Laboratory at Public Health
29 England, Porton Down, was tasked by the Department of Health and Social Care with
30 setting up a national surveillance laboratory facility to study SARS-CoV-2 antibody
31 responses and population-level sero-surveillance in response to the growing SARS-
32 CoV-2 outbreak. In the following 12 months, the laboratory tested more than 160,000
33 samples, facilitating a wide range of research and informing PHE, DHSC and UK
34 government policy. Here we describe the implementation and use of the Euroimmun
35 anti-SARS-CoV-2 IgG assay and provide an extended evaluation of its performance.
36 We present a markedly improved sensitivity of 91.39% (≥ 14 days 92.74%, ≥ 21 days
37 93.59%) compared to our small-scale early study, and a specificity of 98.56%. In
38 addition, we detail extended characteristics of the Euroimmun assay: intra- and inter-
39 assay precision, correlation to neutralisation and assay linearity.

40 2. Introduction

41 Since its emergence in Wuhan, Hubei province, China, in late 2019, the novel severe
42 acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global
43 pandemic of coronavirus 19 disease (COVID-19). A sobering milestone of three million
44 COVID-19 associated deaths globally was reached on April 16 2021, with a cumulative
45 total of more than 150 million SARS-CoV-2 infections reported worldwide¹. The true
46 scale of SARS-CoV-2 infections globally is likely to be much higher with a substantial
47 number of cases of mild or asymptomatic disease being undetected.

48 The UK's first confirmed case of COVID-19 occurred in a person who had travelled
49 from Hubei province to England on 23 January 2020 and became symptomatic three
50 days later². By the end of February, all four countries of the UK had recorded COVID-
51 19 cases and community transmission was established³. Case numbers increased
52 significantly in early March 2020, reaching a total of 6650 laboratory confirmed cases
53 on 23 March⁴ when a national lockdown was implemented. At that time,
54 epidemiological modelling estimated that for every hospitalised COVID-19 case in the
55 UK, there were a further 120-124 infected individuals undetected within the wider
56 community^{4,5}.

57 Individual laboratories began to investigate the use of in-house tests and it became
58 apparent that the UK would benefit from a nationwide service to identify the prevalence
59 of SARS-CoV-2 cases, including asymptomatic ones. Identification of these cases
60 would be essential to inform government policy decisions; to further scientific
61 understanding about immune response evolution, longevity and correlation to
62 protection; and to estimate the true extent of the UK population's exposure to SARS-
63 CoV-2. Additionally, such a service could address related questions such as the

64 performance of alternative SARS-CoV-2 serology assays. However, this work was
65 complicated by logistical issues including the availability of relevant test kits that were
66 in global demand, and the availability of relevant sample sets to validate new assays.
67 Described here is the extended evaluation of the SARS-CoV-2 Euroimmun IgG assay,
68 in addition to establishment of a sero-surveillance laboratory using this assay for over
69 12 months.

70 3. Introduction of an anti-SARS-CoV-2 assay

71 The Rare and Imported Pathogens Laboratory (RIPL) at PHE Porton Down was tasked
72 by the UK Government's Department for Health and Social Care (DHSC) with
73 providing a SARS-CoV-2 serology service in support of a national serosurveillance
74 programme. Testing on this scale would require the use of commercial CE-marked
75 serology kits to guarantee the volumes of supply required, the possibility for
76 automation and the necessary quality control of production batches, with our initial
77 focus on an IgG specific assay. An initial market assessment identified only three
78 companies with production kits available. Of these three kits, one targeted antibodies
79 (IgG) against the SARS-CoV-2 spike protein S1 domain, one targeted nucleocapsid,
80 and the third detected antibodies to an unspecified SARS-CoV-2 antigen. Whilst there
81 is merit in having assays that target different antigens for the determination of
82 differential antibody responses to SARS-CoV-2 infection, the use of spike was judged
83 to be critical for virus entry to cells and therefore an assay detecting spike protein
84 antibodies seemed the most attractive for initial use. Thus, the Euroimmun assay
85 (targeting the S1 domain) was selected for the urgent operational requirement and to
86 also provide an indication of the immune profile of subjects.

87 The laboratory had available existing Stratec Biomedical Gemini platforms (Launch
88 Diagnostics, UK) capable of performing automated ELISAs. After initial ELISA
89 optimisation on the Gemini platform, the first samples were tested to generate initial
90 verification and evaluation data, using samples obtained from patients early in
91 infection and with limited or incomplete clinical data through collaborators/hospitals.

92

93 On the 30th March 2020, PHE Porton Down went live with a COVID-19 serology
94 service for the UK, with an initial capacity of ~800 samples a day. This was later
95 expanded upon addition of two further Gemini platforms, doubling capacity to ~1,600
96 samples a day. Just over 12 months later, as of 31st of April 2021, over 160,000
97 samples have been analysed through this assay and workflow, providing answers to
98 key questions about disease spread and the seroprevalence of SARS-CoV-2 infection,
99 as well as informing outbreak management activities. To date, the Euroimmun assay
100 has helped to deliver several significant studies for the UK population, covering
101 population serosurveillance⁵; healthcare worker exposure⁶; selection of donors for
102 convalescent plasma⁷⁻¹⁰; characterisation of reference standards; and research to
103 determine the durability of the immune response^{6,11,12}.

104

105 4. Methods

106 **Serum samples**

107 Early samples were sourced from collaborating colleagues at PHE Porton Down, PHE
108 Sero-epidemiology Unit Manchester (SEU) and hospitals across England under
109 Material Transfer Agreements (MTAs). These included residual diagnostic sera from
110 SARS-CoV-2 PCR-confirmed samples from hospital in-patients (Guy's and St
111 Thomas' Hospital, The Royal Free, Barnet Hospital and North Hampshire County
112 Hospital, Basingstoke and John Radcliffe Hospital, Oxford), with data available on
113 dates of collection versus onset of disease. Samples collected in Oxford were from
114 individuals consented into 2 studies: Gastro-intestinal illness in Oxford: COVID
115 substudy [Sheffield REC, reference: 16/YH/0247] and Sepsis Immunomics project
116 [Oxford REC C, reference:19/SC/0296]) as described¹³. The large majority of samples
117 were sourced from community cases of SARS-CoV-2 described within the FF100¹⁴
118 and the PHE serology assay evaluation supporting information¹⁵. Of the Oxford patient
119 cohort, 116 patients were classified as having mild disease, 15 severe, 13
120 asymptomatic, 6 critical and 1 death.

121 To validate the Euroimmun assay (and future serology assays), pre-pandemic
122 negative samples were also sourced to determine specificity. These were obtained
123 from serum banks prior to the COVID-19 outbreak by the Royal College of General
124 Practitioners (RCGP) for routine surveillance schemes and held by PHE SEU.

125 **Euroimmun anti-SARS-CoV-2 IgG assay**

126 All testing using the Euroimmun anti-SARS-CoV-2 IgG assay (EI 2606-9601 G,
127 Euroimmun, Lübeck) was performed using an automated microplate processor
128 (Stratec Gemini), which automates all aspect of the ELISA from sample dilution,

129 through to incubations, washing, reading and analysis, according to the
130 manufacturer's instructions for use. Positive and negative kit controls provided by
131 Euroimmun were included with every run, with commercial positive and negative anti-
132 SARS-CoV-2 controls used in parallel (ACCURUN® Anti-SARS-CoV-2 Controls Kit -
133 Series 1000; SeraCare, Gaithersburg) for additional internal quality control. Control
134 values were tracked using a Levy-Jennings plot with Westgard rules applied.

135 The assay is semi-quantitative, with results expressed as a ratio (index) of the
136 extinction (optical density) of the patient sample (or control) over the extinction of the
137 calibrator. Interpretation of samples were defined according to the manufacturer, with
138 an index value of <0.8 defined as negative, >0.8 to 1.1 defined as
139 indeterminate/borderline and ≥ 1.1 interpreted as positive.

140 **Linearity and assay variation**

141 To determine the assay linearity, five high titre serum samples were pooled, with two-
142 fold dilutions generated, and each dilution was run in replicates of five. Similarly, the
143 NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant (20/162, NIBSC, Potters Bar)
144 was run in triplicate across 1:5, 1:10, 1:20, 1:50 and 1:100 dilutions. Results from both
145 the pool and NIBSC calibrant were used to determine the linearity of the Euroimmun
146 assay.

147 The pooled serum samples were additionally used to determine the intra- and inter-
148 assay variation, with five replicates measured each day across five days.


149 **Microneutralisation against SARS-CoV-2**

150 On a panel of 138 convalescent blood donors that were >28 days post-symptom onset,
151 micro-neutralisation titres against SARS-CoV-2 were determined as previously
152 described⁷, with neutralisation titres compared against Euroimmun ratio results.

153 5. Extended verification of the Euroimmun assay

154 In our original small-scale evaluation of the Euroimmun assay, reported in June 2020¹⁶
155 and derived from samples obtained early in the outbreak, 100 PCR-positives samples
156 where the time between sampling and symptom onset was known, were used to
157 determine assay sensitivity, whilst 399 pre-pandemic negatives, 50 serum samples
158 from 2015 seronegative for *Borrelia burgdorferi* and 50 confounder samples (VZV,
159 EBV, CMV and rheumatoid positive) were used to determine specificity (left panel on
160 **Figure 1**). Of the positive panel, 100 samples were initially used but this was later
161 reduced to 93, as seven were found to not be PCR-confirmed. Of the positive samples,
162 67/93 tested positive (≥ 1.1 ratio) on the Euroimmun assay, giving an overall sensitivity
163 of 72.0% (95%CI 61.78-80.86) (**Table 1**, **Figure 3**, PHE Original). When analysing
164 only samples taken ≥ 14 days post-symptom onset, the sensitivity was 73.42% (95%CI
165 62.28-82.73) and at ≥ 21 days, the sensitivity was 74.67% (95%CI 63.30-84.01)¹⁶.

166 Subsequent to our initial establishment of the serosurveillance service using the
167 Euroimmun assay, further commercial immunoassay platforms and kits were
168 evaluated at the request of the DHSC to inform decisions on the use of high-throughput
169 assays by NHS laboratories for the detection of anti-SARS-CoV-2 antibodies in patient
170 samples^{13,17}. As part of this work, we extended our evaluation of the Euroimmun
171 assay. Due to the limited samples and volumes available for the evaluation of high-
172 throughput serology platforms, the panels differed slightly between our initial
173 Euroimmun evaluation and subsequent other commercial assay evaluations
174 performed by PHE Porton Down¹⁵. For the extended evaluation, an additional 592
175 PCR-positive samples that were used for the different verifications of the higher-
176 throughput platforms (including a head-to-head study¹³) were tested using the
177 Euroimmun anti-SARS-CoV-2 IgG assay.



179 *Figure 1: Distribution of evaluation sample results split according to; **Left:** Original evaluation*
180 *(n= 692), and **Right:** Extended evaluation (n=1,799). Dashed lines represent the*
181 *indeterminate range of the Euroimmun assay (ratio or index or s/co ≥ 0.8 and < 1.1).*

182

183 Using this larger panel, the overall sensitivity of the Euroimmun assay was found to
184 be 91.39% (95% CI 89.03% to 93.38%), increasing to 92.74% when using samples
185 with an onset of ≥ 14 days (95% CI 90.49% to 94.60%) and 93.59% when using
186 samples with an onset of ≥ 21 days (95% CI 91.41% to 95.36%), markedly improved
187 from the original evaluation (**Figure 1, Table 1, Figure 3**).

188 Additionally, the specificity panel was expanded from 499 to 1,114 samples: 303
189 confounders (CMV, VZV, EBV and Rheumatoid positive samples), 711 pre-pandemic
190 negatives and 100 Lyme disease negative samples from 2015. Using this panel, a
191 specificity of 98.56% was calculated (95%CI 97.65-99.17%, n=1,114), similar to that
192 from the original evaluation (specificity of 99.0%; 95%CI, 97.5-99.7%).

193 Receiver operating characteristic (ROC) analyses showed the highest area under
194 curve (AUC) value was obtained (0.9902) when using samples from the extended
195 evaluation panel with an interval of ≥ 21 days from onset of symptoms, whilst the
196 original evaluation showed the lowest AUC (0.9584) (**Table 2, Figure 2**).

197 When examining the temporal distribution of the samples used for each of these
198 evaluations, there was variation in the interval since disease/symptom onset (**Figure**
199 **3**). Initial evaluation samples gave the highest frequency of reactive samples at 28
200 days, whilst the extended evaluation showed the highest interval frequency spanning
201 36-43 days after symptom onset. The majority of convalescent samples with intervals
202 of < 21 days tested positive (25 out of 53 samples).

203 This variation in interval distribution is reflected by the difference in the sensitivities
204 seen between the two evaluations. **Figure 3** clearly shows that many of the initial PHE
205 evaluation samples was limited in interval range, in part by sample availability, with
206 samples typically taken between 14 to 35 days after symptom onset. This may account

207 for differences in sensitivities with some samples potentially taken too soon after onset
208 of symptoms to identify any detectable antibody response. Conversely, many of the
209 extended evaluation samples, by their nature, were taken from convalescent patients
210 who had had sufficient interval post onset to generate a strong antibody response.

211 However, it should also be noted that no normalisation for sample demographics (for
212 example differences in geographic location, gender, ethnicity or patient age-ranges)
213 had been applied between datasets, so may have occurred and contributed to
214 differences in sensitivity. Analysis of influence of demographic factors between sample
215 sets is beyond the scope of this overview but may be reported in more detail in
216 individual studies. None of our evaluation sets included longitudinal samples from the
217 same patient.

218 **Table 1:** Sensitivity of the Euroimmun assay from the original PHE evaluation and the
 219 extended evaluation described here. Samples giving an indeterminate value are included with
 220 negative results.

Panel	All samples			Samples >14 days			Samples >21 days		
	n	sensitivity (%)	95% CI	n	sensitivity (%)	95% CI	n	sensitivity (%)	95% CI
Original ¹⁶	93	72.00	61.78% to 80.86%	83	73.42	62.28% to 82.73%	77	74.67	63.30% to 84.01%
Extended	685	91.39	89.03% to 93.38%	600	92.74	90.49% to 94.60%	579	93.59	91.41% to 95.36%

221


222 **Table 2:** ROC analysis values for each of the evaluation panels, with the extended evaluation
 223 described here split by total and intervals of ≥ 14 and ≥ 21 days.

Evaluation	Panel	Area	P value	95% CI	Negatives (incl. confounders)	Positives
Original ¹⁶	Total	0.9584	<0.0001	0.9266 to 0.9902	499	93
Extended	Total	0.9729	<0.0001	0.9631 to 0.9827	1114	685
	≥ 14 days	0.9886	<0.0001	0.9826 to 0.9946	1114	600
	≥ 21 days	0.9902	<0.0001	0.9846 to 0.9958	1114	579

224


225

226



227

228 **Figure 2:** ROC curves for the Euroimmun assay. Curves are shown for the original (n=592)
229 and extended evaluations (n=1,799), with the extended evaluation further split to show
230 samples with intervals of ≥ 14 (n= 1,714) or ≥ 21 days (n= 1,693) after symptom onset. The
231 green box indicates the MHRA Target Product Profile of serology assays (>98% sensitivity
232 and specificity) at >20 days.



233

234 **Figure 3:** An overview of samples by interval distribution and evaluation panel, coloured by
235 the Euroimmun assay result. Top: Original evaluation (n=79). Bottom: Extended evaluation
236 (n=624). The sensitivity at an interval of ≥ 21 days is included in each graph, in line with the
237 MHRA TPP. Red dashed line indicates 14-day interval, blue dashed line indicates 21-day
238 interval.

239

240 6. Further assay characteristics


241 To determine the precision of the Euroimmun assay, five pooled patient samples were
242 used in the absence of an international standard or calibrant at the time to generate a
243 dilution series for linearity and to determine inter- and intra-assay variation, testing five
244 replicates each over five days. The intra-assay and inter-assay variations were found
245 to be <7% and <5% covariance (CV), respectively, indicating high precision when
246 comparing samples across multiple days and replicate samples (Table S1).

247 Similarly, the dilution series was used to determine the linear range of the assay, with
248 an R^2 value of 0.985 (**Figure 4**). As more standards became available, the NIBSC
249 Anti-SARS-CoV-2 Antibody Diagnostic Calibrant was serially diluted to generate
250 additional linearity data, providing a similar R^2 value of 0.955 (**Figure 4**). From the
251 pooled patient sera and the NIBSC calibrant dilutions, the linear range of the assay
252 was determined to lie between index values of 1 and 9. It is noted that the reader
253 configuration on the Gemini platform resulted in strong positive samples that saturated
254 the OD reader and the software assigns an over-read OD value (e.g. 9.999), which
255 can result in an index value of between 25 – 38 depending on the calibrator OD
256 reading. In routine use, the assay was used in a qualitative mode (e.g.
257 positive/negative interpretation respectively) so saturating values were appropriately
258 assigned as positive.

259 Serology assays that have a strong correlation to neutralising antibody titres are useful
260 surrogates for live virus neutralisation assays, which require significant containment
261 level 3 work. Of the 138 samples that were tested by both neutralisation and the
262 Euroimmun assay, 129 were positive on both, whilst nine were only positive by
263 Euroimmun (**Figure 5**), with seven of these samples giving an index result of 1 – 2

264 (close to the indeterminate range). There was a strong correlation between the
265 Euroimmun results and the neutralisation titre, with an R of 0.83 ($R^2 = 0.69$).

266




267

268 **Figure 4:** Dilutions and linear range of the Euroimmun assay, using pooled patient samples
269 (pool; green) and the 20/162 NIBSC Anti-SARS-CoV-2 Antibody Diagnostic Calibrant
270 (calibrant; red). Results >9 were removed due to saturated OD readings. Results with an index
271 of ≥ 1.1 are considered positive whilst those < 0.8 are considered negative, with the
272 indeterminate range (0.8 to 1.1) shown with the dashed black line.

273

274




275

276 **Figure 5:** Comparison of convalescent blood donor serum samples tested using the
277 Euroimmun anti-SARS-CoV-2 IgG assay (Log10 ratio value) and virus neutralisation antibody
278 titre (Log10). Good correlation ($R=0.83$, $R^2=0.69$) was observed between neutralisation and
279 the Euroimmun assay. Blue line indicates linear model, with 95% confidence interval (grey
280 range). Dashed line indicates the positive cut-off value (≥ 1.1 index), whilst the red square
281 shows the mean of the samples negative by neutralisation, but positive by Euroimmun assay.

282 7. Use of the Euroimmun assay in the United Kingdom

283 A number of national and local projects with appropriate ethical approvals have been
284 facilitated through this work and Figure 6 indicates the scope of Euroimmun testing
285 performed by PHE Porton Down between March 2020 to April 2021. Descriptions of
286 some of these projects are highlighted below although more comprehensive analysis
287 is published elsewhere from the respective project groups.



288

289 **Figure 6:** An overview of the number of samples tested using the Euroimmun assay at PHE
290 Porton Down, with total tests (red-dashed line), spanning March 2020 to April 2021. Colours
291 indicate different projects, as described in the text. Projects have since been moved to
292 additional platforms as of March 2021.

293

294 As part of a UK serosurveillance scheme, anonymised residual blood donor samples
295 from people aged 17-84 from different regions of England were sourced from the NHS
296 Blood and Transplant (NHSBT) service to provide additional venous blood samples to
297 determine COVID-19 seroprevalence by age and region. This data began prior to other

298 serosurveillance studies (for example, REACT, ONS) so provided PHE and external
299 modelling groups with the only source of seroprevalence data for the UK at the time.

300 Approximately 10,000 samples were tested monthly and positivity rate on the
301 Euroimmun assay was determined on a weekly basis, to identify the population-level
302 spread of COVID-19 and inform government decision-making. Data was reported to
303 the Public Health England seroepidemiology steering group, scientific pandemic
304 influenza group on modelling (SPI-M) and DHSC, as well as published in the weekly
305 PHE COVID-19 report⁵. This data helped to determine and understand the scale of
306 asymptomatic spread of COVID-19 within the UK population, allowing PHE, DHSC
307 and modellers to assess age groups and areas that are driving transmission.

308 In addition to the NHSBT serosurveillance, blood samples were obtained from patients
309 visiting primary care settings via the Royal College of General Practitioners (RCGP)
310 Research and Surveillance Centre to determine COVID-19 seroprevalence, with a
311 total of 24,927 samples tested since March 2020.

312 As part of a collaboration between PHE and NHSBT, convalescent plasma donor
313 samples were tested to determine which donations should be provided for clinical trials
314 assessing the therapeutic effects of convalescent plasma treatment of patients with
315 COVID-19 (NHSBT Conv). The Euroimmun assay was chosen as the results showed
316 a good correlation with neutralisation assays^{7,8}; and donations with a Euroimmun
317 serology index result of >9.1 (later revised to 6.0) were shown to be associated with
318 the presence of high neutralising antibody titres of 1:100 or higher^{7,8} and were hence
319 selected for trial use. Serological testing in support of this project began in April 2020,
320 with the first patients receiving treatment in the beginning of May as part of the
321 REMAP-CAP trial¹⁰ and subsequently via the RECOVERY trial⁹.

322 Whilst laboratory antibody testing using ELISAs is considered the gold-standard for
323 determining population-level exposure to SARS-CoV-2, additional studies were
324 conducted to determine the feasibility of using lateral flow device antibody tests. On
325 request from DHSC, a study was performed on emergency service workers to evaluate
326 the utility of home antibody testing kits; EDSAB-HOME (Evaluating Detection of
327 SARS-CoV-2 AntiBodies at HOME). Capillary blood samples from >2,500 volunteers
328 were tested on different lateral flow devices and a contemporaneous venous sample
329 was tested on the Euroimmun assay as the reference test¹⁸.

330 From the start of the first COVID-19 lockdown in the UK (23 March 2020), the
331 COVIDsortium study (NCT04318314) collected serial samples from a cohort of 731
332 healthcare workers (HCW) with the aim of identifying host and pathogen correlates of
333 protection and pathogenesis in mild/asymptomatic SARS-CoV-2 infection^{19,20}. The
334 Euroimmun assay was used throughout to characterise the serostatus of all study
335 samples which by completion of the final follow-up samples at 1 year, will number
336 more than 13,000 samples. This data helped to define the proportion of this HCW
337 cohort who seroconverted, and was used to monitor the longitudinal antibody
338 response and rate of decline of anti-S1 IgG antibodies⁶ and to investigate the
339 relationship between peak anti-S1 IgG titre and neutralising antibody titre²¹.

340 In addition, a small project (ESCAPE) began in March 2020 as a mechanism to study
341 antibody responses to infection. A cohort of Public Health England staff across 4 sites
342 were recruited, with monthly blood donations taken as a way to understand the kinetics
343 of antibodies post-infection¹¹.

344 A collaboration between PHE and Hampshire Hospitals NHS Foundation Trust
345 (HHFT), provided 1885 serial samples from 282 hospital in-patients with acute COVID-

346 19 and 189 serial samples from 50 convalescent HCWs (the PDASH study). All
347 participants had PCR confirmed SARS-CoV-2 infections that ranged from
348 asymptomatic to severe disease. The study used the Euroimmun assay to determine
349 the time to seroconversion and to monitor the longitudinal antibody response in study
350 participants.

351 Other projects included those used specifically for serology assay evaluations
352 conducted by PHE Porton and PHE SEU, smaller research studies, and those
353 conducted by hospitals and colleagues early in the pandemic.

354

355 8. Discussion

356 The Euroimmun assay has been fundamental to the UK's public health response to
357 COVID-19, with >160,000 samples tested March 2020 to March 2021 (**Figure 6**). This
358 early availability of the assay was key to performing seroprevalence testing in the early
359 stages of the pandemic, informing the policy and legislative responses of PHE, DHSC
360 and the UK Government. It also contributed to our understanding of immune
361 responses during COVID-19 infection and recovery as well as provided real-time (~24
362 hours) testing of convalescent plasma before being provided for use in clinical trials.

363 Whilst many platforms and assays now exist for the detection of anti-SARS-CoV-2
364 antibodies (including those evaluated by ourselves²²), there were limited choices
365 available at the onset of the pandemic in the UK in March 2020. This highlights the
366 need and basis for pandemic preparedness from an immunology and serology
367 perspective, with the requirement for labs to be able to run high-throughput antibody
368 tests on specimens from patients infected with newly emerging pathogens. Rapid
369 immunology research on a new pathogen enables early understanding of potential
370 immunity and inform early vaccine design. Whilst in-house/research-based assays
371 were available since January 2020, these require significant quality control to ensure
372 consistent diagnosis across batches of samples to ensure consistent sensitivity.
373 Similarly, in-house assays can also suffer from logistical and supply issues for
374 specially manufactured components (recombinant proteins etc). Commercial assays
375 became rapidly available with the spread of SARS-CoV-2 in early 2020, however
376 supply and logistical issues were also evident with the global spread of SARS-CoV-2,
377 so this should be a factor in deciding on assays for serosurveillance.

378

379 In our original evaluation, we found an overall sensitivity of 72.0% (interval ≥ 14 days:
380 73.42%, interval ≥ 21 days: 74.67%) and a specificity of 99.0% for the Euroimmun
381 assay, whilst the extended evaluation detailed here found an overall sensitivity of
382 91.39% (interval ≥ 14 days: 92.74%, interval ≥ 21 days: 93.59%) and a specificity of
383 98.56% (**Table 1, Figure 2**). This data is supported by other studies, which have
384 shown similar high sensitivities of 90%²³, 96%²⁴ and 100%²⁵. The initial evaluation
385 suggested a moderate sensitivity for the Euroimmun assay, but this is likely a reflection
386 of the early stages of the pandemic, when serum from patients with confirmed COVID-
387 19 were extremely difficult to obtain, disease onset was poorly characterised and little
388 convalescent material was available. This limited the number of samples, as many of
389 the original evaluation samples were obtained from patients with mild disease within
390 the community, so in using these particular samples, this could have resulted in lower
391 sensitivity than anticipated, due to mild infections and resulting in lower antibody
392 responses than those with severe infections or those requiring hospitalisation²⁶. In
393 addition, timing between disease onset and sample date was not fully established for
394 all patient samples, with many taken from patients too early since disease onset,
395 whereby no robust IgG/immunological response is mounted.

396 Use of an extended sample panel has enabled us to better evaluate the Euroimmun
397 assay. Although the Euroimmun assay showed improved sensitivity in our extended
398 evaluation, in our analysis, it still does not meet the MHRA's Target Product Profile
399 (TPP) of >98% sensitivity recommendation for SARS-CoV-2 serology assays to
400 determine if people have recent infection of SARS-CoV-2²⁷; it does however meet the
401 TPP of >98% specificity.

402 In addition to improved sensitivity using this extended panel, intra- and inter-assay
403 variation was found to be low, with covariance of <7% and <5%, respectively. Using

404 pooled patient samples and the NIBSC diagnostic calibrant, the linear range of the
405 assay was also determined, enabling semi-quantitative comparisons (**Figure 4**). Our
406 results are consistent with other studies that show that only a defined range of the
407 Euroimmun assay can be used to reliably infer a linear range⁶.

408 As an anti-spike (S1 domain) antibody ELISA, the Euroimmun assay results also
409 correlate with neutralising antibody titres ($R=0.83$, $R^2=0.69$) as shown elsewhere^{7,8,28},
410 suggesting that this assay provides a useful surrogate for virus neutralisation and
411 possible correlation to immune protection (**Figure 5**), without the requirement for
412 containment level 3 facilities and live-virus culture. However, other pseudo-type
413 assays have shown higher correlation²⁸, likely due to the different dynamics between
414 antibody-binding assays and neutralisation-based assays.

415 In addition, as an indirect sandwich ELISA, results are only semi-quantitative and
416 display a maximum reading for optical densities due to reader saturation. In our
417 equipment implementation depending on the calibrator value, max OD values can then
418 result in an index value of between approximately 26 and 38, preventing direct
419 comparisons between samples unless the calibrator values are similar or are within
420 the linear range of the assay, determined here to be between OD values of 1 and 9,
421 (**Figure 4**). If quantitative results are desired, our recommendation is to dilute samples
422 that are strongly positive to within this range.

423 Notably, of the serology assays evaluated by PHE Porton Down to date²², the
424 Euroimmun assay format does not require the installation of dedicated
425 machinery/specialist equipment, similar to other plate-based ELISA assays. This
426 enables wider use of the assay: it can be utilised in most laboratory settings using
427 automated pipetting platforms (such as the Stratec Gemini), or on the bench with

428 manual pipetting, or within the field since only limited additional laboratory equipment
429 such as a plate reader is required.

430 Serology assay selection for different requirements is complex²⁹. This initial
431 programme was principally focused on serosurveillance, further work is now underway
432 at PHE Porton to determine antibody responses induced by vaccination³⁰, vaccine
433 effectiveness³¹, vaccine coverage, variant infection and population spread³², using a
434 combination of serology assays targeting different antigens. With additional assays
435 now available, we have expanded our assays to encompass those with improved
436 sensitivity and specificity, with the capability to change rapidly, enabling better and
437 more accurate analysis of the differing and refined responses to the SARS-CoV-2.
438 Newer assays have enabled us to determine specific protein sub-domain responses
439 (e.g. anti-RBD), as well as using a combination of assays as a mechanism to
440 differentiate between those with previous infection (presence of both anti-spike and
441 anti-nucleocapsid antibodies), those with vaccination and no previous infection
442 (presence of only anti-spike antibodies) and those with previous infection and
443 vaccination (presence of both anti-spike and anti-nucleocapsid antibodies, with
444 significantly higher anti-spike responses as reported elsewhere³⁰).

445 9. Acknowledgements and funding

446 We thank the many scientists and clinicians that provided PHE Porton with early
447 samples from those with PCR-confirmed SARS-CoV-2 infection in March 2020,
448 including those at Guy's and St Thomas' Hospital, Westminster, Royal Free Hospital,
449 Barnet and North Hampshire County Hospital, Basingstoke. In addition, we thank
450 collaborators from the head-to-head study at Oxford University (Gillian Rodger,
451 Hayleah Pickford, Teresa Street, Kate Dingle, Justine Rudkin, Derrick Crook, David
452 Eyre, Philippa Matthews and Nicole Stoesser).

453 This project was funded as part of the DHSC serological assay evaluation procedure.
454 AJM and DTS are funded by ISARIC-4C "Medical Research Council (grant
455 MC_PC_19059) as part of the ISARIC Coronavirus Clinical Characterisation
456 Consortium (ISARIC-4C)", COMBAT Consortium, OUH clinical and research staff and
457 patients

458 10. Author contributions

459 ADO and AB wrote the manuscript. AB, DB, ADO, SD'A, TB, AS, MC, PP, AS and RV
460 performed and oversaw the initial evaluation and assay implementation. ADO, AB and
461 SD'A performed the extended assay characterisation. AB, ST, JH, CR and SD'A were
462 responsible for routine testing. EL provided initial evaluation samples and EL & AS
463 facilitated with sourcing samples. AJM and DTS provided additional evaluation
464 samples. AL, HH and MZ were responsible for the microneutralisation work. All
465 authors read and commented on the final manuscript.

466

467

468 11. References

- 469 1. World Health Organization. COVID-19 Weekly Epidemiological Update 22.
470 *World Heal. Organ.* 1–3 (2021).
- 471 2. Lillie, P. J. *et al.* Novel coronavirus disease (Covid-19): The first two patients in
472 the UK with person to person transmission. *Journal of Infection* **80**, 578–606
473 (2020).
- 474 3. Chappell, J. G. *et al.* Retrospective screening of routine respiratory samples
475 revealed undetected community transmission and missed intervention
476 opportunities for SARS-CoV-2 in the United Kingdom. *medRxiv*
477 2020.08.18.20174623 (2020). doi:10.1101/2020.08.18.20174623
- 478 4. Public Health England. *National COVID-19 surveillance reports.* (2020).
- 479 5. Public Health England. *Public Health England National flu and COVID-19*
480 *surveillance reports.*
- 481 6. Manisty, C. *et al.* Time series analysis and mechanistic modelling of
482 heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2
483 infection. *EBioMedicine* **65**, 103259 (2021).
- 484 7. Harvala, H. *et al.* Convalescent plasma therapy for the treatment of patients with
485 COVID-19: Assessment of methods available for antibody detection and their
486 correlation with neutralising antibody levels. *Transfus. Med.* 1–9 (2020).
487 doi:10.1111/tme.12746
- 488 8. Harvala, H. *et al.* Convalescent plasma treatment for SARS-CoV-2 infection:
489 analysis of the first 436 donors in England, 22 April to 12 May 2020.
490 *Eurosurveillance* **25**, 2001260 (2020).

- 491 9. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
492 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label,
493 platform trial. *Lancet* (2021). doi:10.1016/S0140-6736(21)00897-7
- 494 10. REMAP-CAP Investigators, Estcourt, L. J. Convalescent Plasma in Critically ill
495 Patients with Covid-19. *medRxiv* 2021.06.11.21258760 (2021).
- 496 11. Harris, R. J. *et al.* Serological surveillance of SARS-CoV-2: Six-month trends
497 and antibody response in a cohort of public health workers. *J. Infect.* 1–25
498 (2021). doi:10.1016/j.jinf.2021.03.015
- 499 12. Amirthalingam, G. *et al.* Seroprevalence of SARS-CoV-2 among Blood Donors
500 and Changes after Introduction of Public Health and Social Measures, London,
501 UK. *Emerg. Infect. Dis.* **27**, 1795–1801 (2021).
- 502 13. Ainsworth, M. *et al.* Performance characteristics of five immunoassays for
503 SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect. Dis.* **20**,
504 1390–1400 (2020).
- 505 14. Boddington, N. L. *et al.* COVID-19 in Great Britain: Epidemiological and clinical
506 characteristics of the first few hundred (FF100) cases: A descriptive case series
507 and case control analysis. *medRxiv* (2020). doi:10.1101/2020.05.18.20086157
- 508 15. Public Health England. *Supporting information for the PHE commercial serology*
509 *assay evaluations.*
- 510 16. Public Health England. *Evaluation of the Euroimmun Anti-SARS-CoV-2 ELISA*
511 *(IgG) serology assay for the detection of anti-SARS-CoV-2 antibodies.* (2020).
- 512 17. Public Health England. *Evaluation of sensitivity and specificity of four*
513 *commercially available SARS-CoV-2 antibody immunoassays.* (2020).

- 514 18. Mulchandani, R. *et al.* Accuracy of UK Rapid Test Consortium (UK-RTC) ‘abC-
515 19 Rapid Test’ for detection of previous SARS-CoV-2 infection in key workers:
516 Test accuracy study. *BMJ* **371**, (2020).
- 517 19. Moon, J. C. *et al.* Healthcare Workers Bioresource: Study outline and baseline
518 characteristics of a prospective healthcare worker cohort to study immune
519 protection and pathogenesis in COVID-19. *Wellcome Open Res.* **5**, (2020).
- 520 20. Treibel, T. A. *et al.* COVID-19: PCR screening of asymptomatic health-care
521 workers at London hospital. *The Lancet* **395**, 1608–1610 (2020).
- 522 21. Reynolds, C. J. *et al.* Discordant neutralizing antibody and T cell responses in
523 asymptomatic and mild SARS-CoV-2 infection. *Sci. Immunol.* **5**, (2020).
- 524 22. Public Health England. COVID-19: laboratory evaluations of serological assays.
525 *GOV.UK* (2021). Available at:
526 [https://www.gov.uk/government/publications/covid-19-laboratory-evaluations-](https://www.gov.uk/government/publications/covid-19-laboratory-evaluations-of-serological-assays)
527 [of-serological-assays.](https://www.gov.uk/government/publications/covid-19-laboratory-evaluations-of-serological-assays) (Accessed: 2nd June 2021)
- 528 23. Lassaunière, R. *et al.* Evaluation of nine commercial SARS-CoV-2
529 immunoassays. *medRxiv* 2020.04.09.20056325 (2020).
530 doi:10.1101/2020.04.09.20056325
- 531 24. GeurtsvanKessel, C. H. *et al.* An evaluation of COVID-19 serological assays
532 informs future diagnostics and exposure assessment. *Nat. Commun.* **11**, (2020).
- 533 25. Manalac, J. *et al.* Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and
534 Euroimmun ELISA IgG/IgA assays in a clinical lab. *Clin. Chim. Acta* **510**, 687–
535 690 (2020).
- 536 26. Rijkers, G. *et al.* Differences in antibody kinetics and functionality between

- 537 severe and mild severe acute respiratory syndrome Coronavirus 2 infections. *J.*
538 *Infect. Dis.* **222**, 1265–1269 (2020).
- 539 27. MHRA. Target Product Profile: antibody tests to help determine if people have
540 recent infection to SARS-CoV-2: Version 2. Available at:
541 [https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-antibody-tests-to-help-determine-if-people-have-recent-infection-to-sars-cov-2-version-2)
542 [coronavirus-covid-19-work/target-product-profile-antibody-tests-to-help-](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-antibody-tests-to-help-determine-if-people-have-recent-infection-to-sars-cov-2-version-2)
543 [determine-if-people-have-recent-infection-to-sars-cov-2-version-2](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-antibody-tests-to-help-determine-if-people-have-recent-infection-to-sars-cov-2-version-2). (Accessed:
544 8th April 2021)
- 545 28. Lamikanra, A. *et al.* Comparability of six different immunoassays measuring
546 SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent
547 plasma: From utility to prediction. *Transfusion* **61**, 2837–2843 (2021).
- 548 29. Peeling, R. W. *et al.* Serology testing in the COVID-19 pandemic response.
549 *Lancet Infect. Dis.* **20**, e245–e249 (2020).
- 550 30. Manisty, C. *et al.* Antibody response to first BNT162b2 dose in previously SARS-
551 CoV-2-infected individuals. *Lancet* (2021). doi:10.1016/S0140-6736(21)00501-
552 8
- 553 31. Hall, V. J. *et al.* COVID-19 vaccine coverage in health-care workers in England
554 and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
555 prospective, multicentre, cohort study. *Lancet (London, England)* 1725–1735
556 (2021). doi:10.1016/S0140-6736(21)00790-X
- 557 32. Whitaker, H. *et al.* Impact of COVID-19 Vaccination Program on Seroprevalence
558 in Blood Donors in England, 2021. *J. Infect.* (2021).
559 doi:10.1016/j.jinf.2021.04.037

560

561

562

563 **Table S1:** Precision results for the Euroimmun assay using five pooled patient sera.

564 Samples were tested in replicates of five over five days. Intra-assay variation was

565 <7%, whilst inter-assay variation was <5%

Sample		Day 1	Day 2	Day 3	Day 4	Day 5	Inter-assay Mean	Inter-assay SD	Inter-assay CV
1	Mean	9.00	8.43	8.59	8.43	8.64	8.62	0.235	2.724
	SD	0.26	0.13	0.14	0.08	0.13			
	CV	2.93	1.59	1.60	0.99	1.50			
2	Mean	6.28	5.95	5.99	6.04	6.12	6.08	0.132	2.180
	SD	0.11	0.19	0.13	0.16	0.28			
	CV	1.69	3.26	2.18	2.64	4.50			
3	Mean	3.72	3.52	3.55	3.67	3.67	3.62	0.087	2.409
	SD	0.11	0.12	0.04	0.19	0.11			
	CV	2.84	3.52	1.13	5.17	2.93			
4	Mean	2.07	1.90	1.99	1.99	1.99	1.99	0.062	3.102
	SD	0.04	0.03	0.06	0.09	0.08			
	CV	2.16	1.72	3.12	4.42	4.04			
5	Mean	1.07	0.98	1.02	0.99	1.03	1.02	0.037	3.620
	SD	0.07	0.01	0.04	0.02	0.07			
	CV	6.28	0.55	3.76	2.46	6.60			

566

567

568 **Table S2: Determination of linear range of EuroImmun assay using serially**
569 **diluted pooled patient sera.** Pooled serum samples at dilutions of 2, 4 and 8 were
570 removed due to OD saturation.

Source	Dilution	Index (mean)	SD	
Patient pool	16	8.617	0.235	
	32	6.077	0.132	
	64	3.624	0.087	
	128	1.987	0.062	
	256	1.018	0.037	
	Calibrant	5	7.636	0.793
10		6.000	0.279	
20		3.673	0.261	
50		1.820	0.100	
100		1.029	0.045	
200		0.614	0.013	

571

572

573 12. Appendix 1

574 **PHE Porton Euroimmun testing group** list of authors:

575 Joanna Bacon, Daniel Bailey, Natalie Baker, Jack Bleach, Debbie Blick, Paul Bolton,
576 Abbie Bown, Olivia Carr, Matthew Catton, Melanie Clifford, Tom Coleman, Charlie
577 Cooper, Charlotte Cornbill, Ellie Cross, Mollie Curran-French, Silvia D’Arcangelo,
578 Owen Daykin-Pont, Charlotte Dixon, Phoebe Do Carmo Silva, Ellie Drinkwater, Jackie
579 Duggan, Xena Dyball, Jack Easton, Ruth Elderfield, Anaya Ellis, Jenna Furneaux,
580 Harriet Garland, Barry Gibney, Supriya Gurung, Rachel Halkerston, Robin Hanson,
581 James Hardy, Alexander Hargreaves, Gabrielle Harker, Becky Harrison, Bethany
582 Hicks, Charlotte Hind, Emma Hobbs, James Hogg, Margarita Jablonska, Leah Johal,
583 Caoimhe Kelly, Carensa Knights, Emily Laing, Deborah Lister, Rosa Loffredo, Adam
584 Mabbutt, Bethany Martin, Felicity Marx, Lara Mason, Joanna McGlashan, Debbie
585 McKee, Isobel Miles, Sebastian Millward, Gloria Mongelli, Christopher Moon, Taalia
586 Morgan, Alexandra Morrison, Alexandra Morrison, Anna Moy, Josh Nelthorpe-Cowne,
587 Jack Nevols, Jane Osbourne, Jodie Owen, Ros Packer, Jordan Pascoe, Prem
588 Perumal, Esther Picton-Barlow, Eleanor Porges, Saskia Proud, Deen Qureshi,
589 Anastasia Richardson, April Roberts, Adam Roberts, Amanda Semper, Lauren
590 Setterfield, Jennifer Small, Kirstie Speer, Sara Speight, Angela Sweed, Stephen
591 Taylor, Steve Thomas, Sian Tiley, Elizabeth Truelove, Ann Varghese, Richard Vipond,
592 Rosie Watts, Katie West, Clare Wilson, Kate Withycombe, Charlotte Woolley.